About Human Papillomavirus Type 16 (HPV16) E7 Recombinant Protein

Human Papillomavirus Type 16 (HPV16) is the most prevalent high-risk papillomavirus associated with cervical cancer, anogenital cancers, and a large proportion of HPV-positive head and neck cancers. The E7 protein is a major viral oncoprotein that promotes malignant transformation by binding and inactivating members of the retinoblastoma (pRb) tumor suppressor family, leading to deregulated cell-cycle progression and uncontrolled cellular proliferation. Persistent expression of E7 is essential for the development and maintenance of HPV-associated cancers, making it a key target for therapeutic vaccine development, cancer immunotherapy, and tumor immunology research.

eEnzyme's Human HPV16 E7 Recombinant Protein is produced for research use and is suitable for studies of HPV oncogenesis, T-cell immune responses, antibody generation, ELISA development, Western blotting, epitope mapping, and therapeutic vaccine evaluation. This recombinant protein provides a valuable reagent for investigating HPV16-associated malignancies, host immune responses, and the development of next-generation immunotherapies targeting HPV-driven cancers.

Applications

Biological Significance of HPV16 E7

HPV16 E7 is one of the principal viral oncoproteins responsible for HPV-induced carcinogenesis. By inactivating the pRb tumor suppressor pathway, E7 promotes uncontrolled cell proliferation and contributes to the initiation and maintenance of HPV-associated tumors. Because E7 is continuously expressed in many HPV-positive cancers, it remains one of the most important tumor-associated antigens for therapeutic vaccine development and cancer immunotherapy. The HPV16 E7 Recombinant Protein provides a valuable research tool for studying HPV biology, antigen-specific immune responses, and the development of novel therapeutic strategies against HPV-associated malignancies.